Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma

Journal of Cutaneous Pathology

Volumn 40, Issue 10, 2013, Pages 884-886

  Clarke, Michael ^a,b   Ortel, Bernhard ^a,b   Brockstein, Bruce ^a,b   Rojanapremsuk, Theera ^a,b   Victor, Thomas ^a,b   Thomas, Antoinette ^a,b   Cibull, Thomas ^a,b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Braf; cutaneous neoplasm; leiomyoma; malignant melanoma

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE; VEMURAFENIB;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRAF; CASE REPORT; CHEMICALLY INDUCED DISORDER; CUTANEOUS NEOPLASM; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; LEIOMYOMA; MALE; MELANOMA; MISSENSE MUTATION; PATHOLOGY; SECOND CANCER; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED;

BRAF; CUTANEOUS NEOPLASM; LEIOMYOMA; MALIGNANT MELANOMA;

AGED; AMINO ACID SUBSTITUTION; HUMANS; INDOLES; LEIOMYOMA; MALE; MELANOMA; MUTATION, MISSENSE; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84884901800     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12199     Document Type: Article

References (9)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277.
2. Smalley K, Sondak V,. Melanoma-an unlikely poster child for personalized cancer therapy. N Engl J Med 2010; 363: 876.
3. Wellbrock C, Hurlstone A,. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010; 80: 561.
4. Long G, Menzies A, Nagrial A, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239.
5. Chu E, Wanat K, Rosenbach M, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012; 67: 1265.
6. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207.
7. Callahan M, Rampal R, Harding J, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012; 367: 2316.
8. Karbowniczek M, Henske E,. The role of tuberin in cellular differentiation: are B-Raf and MAPK involved? Ann N Y Acad Sci 2005; 1059: 168.
9. Gokdemir G, Sakiz D, Koslu A,. Multiple cutaneous leiomyomas of the nipple. J Eur Acad Dermatol Venereol 2006; 20: 468.